BACKGROUND AND OBJECTIVES: The prevalence of mineral metabolism abnormalities is almost universal in stage 5 chronic kidney disease (CKD), but the presence of abnormalities in milder CKD is not well characterized. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data on adults > or =20 yr of age from the National Health and Nutrition Examination Survey 2003-2004 (N = 3949) were analyzed to determine the association between moderate declines in estimated GFR (eGFR), calculated using the Modfication of Diet in Renal Disease formula, and serum intact parathyroid hormone (iPTH) > or = 70 pg/ml. RESULTS: The geometric mean iPTH level was 39.3 pg/ml. The age-standardized prevalence of elevated iPTH was 8.2%, 19.3%, and 38.3% for participants with eGFR > or = 60, 45 to 59, and 30 to 44 ml/min/1.73 m(2), respectively (P-trend < 0.001). After adjustment for age; race/ethnicity; sex; menopausal status; education; income; cigarette smoking; alcohol consumption; body mass index; hypertension; diabetes mellitus; vitamin D supplement use; total calorie and calcium intake; and serum calcium, phosphorus, and 25-hydroxyvitamin D levels-and compared with their counterparts with an eGFR > or = 60 ml/min/1.73 m(2)-the prevalence ratios of elevated iPTH were 2.30 and 4.69 for participants with an eGFR of 45 to 59 and 30 to 44 ml/min/1.73 m(2), respectively (P-trend < 0.001). Serum phosphorus > or = 4.2 mg/dl and 25-hydroxyvitamin D < 17.6 ng/ml were more common at lower eGFR levels. No association was present between lower eGFR and serum calcium < 9.4 mg/dl. CONCLUSIONS: This study indicates that elevated iPTH levels are common among patients with moderate CKD.
BACKGROUND AND OBJECTIVES: The prevalence of mineral metabolism abnormalities is almost universal in stage 5 chronic kidney disease (CKD), but the presence of abnormalities in milder CKD is not well characterized. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data on adults > or =20 yr of age from the National Health and Nutrition Examination Survey 2003-2004 (N = 3949) were analyzed to determine the association between moderate declines in estimated GFR (eGFR), calculated using the Modfication of Diet in Renal Disease formula, and serum intact parathyroid hormone (iPTH) > or = 70 pg/ml. RESULTS: The geometric mean iPTH level was 39.3 pg/ml. The age-standardized prevalence of elevated iPTH was 8.2%, 19.3%, and 38.3% for participants with eGFR > or = 60, 45 to 59, and 30 to 44 ml/min/1.73 m(2), respectively (P-trend < 0.001). After adjustment for age; race/ethnicity; sex; menopausal status; education; income; cigarette smoking; alcohol consumption; body mass index; hypertension; diabetes mellitus; vitamin D supplement use; total calorie and calcium intake; and serum calcium, phosphorus, and 25-hydroxyvitamin D levels-and compared with their counterparts with an eGFR > or = 60 ml/min/1.73 m(2)-the prevalence ratios of elevated iPTH were 2.30 and 4.69 for participants with an eGFR of 45 to 59 and 30 to 44 ml/min/1.73 m(2), respectively (P-trend < 0.001). Serum phosphorus > or = 4.2 mg/dl and 25-hydroxyvitamin D < 17.6 ng/ml were more common at lower eGFR levels. No association was present between lower eGFR and serum calcium < 9.4 mg/dl. CONCLUSIONS: This study indicates that elevated iPTH levels are common among patients with moderate CKD.
Authors: Mark D Danese; John Kim; Quan V Doan; Michelle Dylan; Robert Griffiths; Glenn M Chertow Journal: Am J Kidney Dis Date: 2006-01 Impact factor: 8.860
Authors: J-C Souberbielle; A Boutten; M-C Carlier; D Chevenne; G Coumaros; E Lawson-Body; C Massart; M Monge; J Myara; X Parent; E Plouvier; P Houillier Journal: Kidney Int Date: 2006-06-21 Impact factor: 10.612
Authors: Marieke B Snijder; Rob M van Dam; Marjolein Visser; Dorly J H Deeg; Jacqueline M Dekker; Lex M Bouter; Jaap C Seidell; Paul Lips Journal: J Clin Endocrinol Metab Date: 2005-04-26 Impact factor: 5.958
Authors: Linda F Fried; Mary Louise Biggs; Michael G Shlipak; Stephen Seliger; Bryan Kestenbaum; Catherine Stehman-Breen; Mark Sarnak; David Siscovick; Tamara Harris; Jane Cauley; Anne B Newman; John Robbins Journal: J Am Soc Nephrol Date: 2006-12-13 Impact factor: 10.121
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: T Alarcón; J I González-Montalvo; R Hoyos; J Diez-Sebastián; A Otero; J L Mauleon Journal: J Endocrinol Invest Date: 2015-06-06 Impact factor: 4.256
Authors: Anna Jovanovich; Michel Chonchol; Alfred K Cheung; James S Kaufman; Tom Greene; William L Roberts; Gerard Smits; Jessica Kendrick Journal: Clin J Am Soc Nephrol Date: 2012-03-01 Impact factor: 8.237
Authors: C Barrett Bowling; Lesley A Inker; Orlando M Gutiérrez; Richard M Allman; David G Warnock; William McClellan; Paul Muntner Journal: Clin J Am Soc Nephrol Date: 2011-10-27 Impact factor: 8.237
Authors: Stephen B Kritchevsky; Janet A Tooze; Rebecca H Neiberg; Gary G Schwartz; Dorothy B Hausman; Mary Ann Johnson; Douglas C Bauer; Jane A Cauley; M Kyla Shea; Peggy M Cawthon; Tamara B Harris; Susan M Rubin; Francis A Tylavsky; Denise K Houston Journal: J Clin Endocrinol Metab Date: 2012-08-31 Impact factor: 5.958
Authors: Sherif El Desoky; Youssef M K Farag; Eatidal Safdar; Mohamed Ahmed Shalaby; Ajay K Singh; Jameela A Kari Journal: Indian J Pediatr Date: 2016-01-30 Impact factor: 1.967